Abstract:Background:Hypofibrinogenemia is a serious adverse reaction related to tigecycline administered against multidrug-resistant (MDR) bacteria and can lead to therapy termination. High dose and prolonged tigecycline therapy, renal failure, and base level of fibrinogen (FIB) were reported risk factors of tigecycline-associated FIB reduction. But results are unknown in patients with renal transplantation.Methods:A single-center and a case-control study involving renal transplantation patients was conducted. From January, 2017 to January, 2020, patients with a tigecycline course more than 2 days and a baseline FIB level greater than 2 g/L were enrolled. Hypofibrinogenemia was defined as plasma FIB <2.0 g/L. The extent of FIB reduction was calculated based on the baseline of FIB level before tigecycline administration. FIBRO was defined as the extent of FIB reduction over 50%, and FIBRB referred to the extent of FIB reduction below 50%. Univariate and multivariate analyses were performed by logistic regression models to identify independent risk factors of tigecycline-associated FIB reduction.Results:In total, 120 patients were enrolled. A total of 114 patients (95.00%) developed with hypofibrinogenaemia. Hypofibrinogenemia mainly occurred 3 days after tigecycline administration. Of them, 79 (65.83%) developed FIBRO with a median occurrence of 3 [2-4] days after initiation of tigecycline. Multivariable regression analysis demonstrated that the FIB level before tigecycline use [odds ratio (OR): 3.225, 95% confidence interval (CI): 1.801-5.772] and total tigecycline dose (OR: 4.930, 95% CI: 1.433-16.959) were risk factors for FIBRO.Conclusions:The FIB level before tigecycline use and total tigecycline dose were significantly associated with FIBRO, suggesting that FIB level and coagulation-related indicators should be closely monitored during tigecycline treatment to avoid life-threatening bleeding events.

Effects of Gatifloxacin on plasma digoxin levels in rabbits

Adverse Drug Reactions Induced by Gatifloxacin:Analysis of 866 Cases During 2003～2006

Influence of Pazufloxacin Mesilate on Pharmacokinetics of Aminophylline in Rabbits

[Effect of Adriamycin on Sarcoplasmic Reticulum Ca2+ -Atpase Activity in Cardiomyocyte of Rabbits]

Recipe Analysis of Digoxin in Outpatients from a Perspective of Pharmacokinetic Interaction

Risk Factors of Tigecycline-Associated Fibrinogen Reduction in Patients with Renal Transplantation: a Case-Control Study

Pharmacokinetics of Gatifloxacin in Ocular Aqueous Humors of Rabbit

Distribution of Compound Gatifloxacin Eye Drops in Ocular Tissues and Its Pharmacokinetics in Rabbits

Effects of Fructose-1,6-diphosphate on Concentration of Calcium and Activities of Sarcoplosnic Ca2+-ATPase in Cardiomyocytes of Adriamycin-treated Rats.

Effects of gatifloxacin and levofloxacin on blood glucose:a retrospective cohort study

Cardioprotective Effects of Glycyrrhiza Uralensis Extract Against Doxorubicin-Induced Toxicity.

Doxorubicin induced rabbit myocardium injury and protective effect of murine on myocardium

A follow-up study of effects of gatifloxacin on blood glucose in inpatients

Pharmacological Effect of Digoxin on some cardiac electrical properties and clinical signs in the Rabbit Model

Effect of ketamine on pharmacokinetics of efavirenz in rabbits

Pharmacokinetic Analysis of Gatifloxacin and Dexamethasone in Rabbit Ocular Biofluid Using a Sensitive and Selective LC–MS/MS Method

Influence of OATP1B1 and OATP1B3 Mutations and Glomerular Filtration Rate on Trough Serum Digoxin Concentration in the Chinese Population

Effects of 2-hydroxypropyl-beta-cyclodextrin on pharmacokinetics of digoxin in rabbits and humans

Pharmacokinetics of Diammonium Glycyrrhizinate Effervescent Granules in Rabbits

Monitoring of blood digoxin concentration and analysis of the efficacy and toxicity of diogxin

A Double-Blind, Randomized Controlled Clinical Study:Gatifloxacin Vs Levofloxacin in Treatment of 98 Patients with Urinary Tract Infections